Results of image guided brachytherapy for stage IB cervical cancer in the RetroEMBRACE study

Forfattere Petric P, Lindegaard JC, Sturdza A, Fokdal L, Kirchheiner K, Tan LT, Schmid MP, Haie-Meder C, Jürgenliemk-Schulz IM, van Limbergen E, Hoskin P, Gillham C, Tharavichitkul E, Mahantshetty U, Villafranca E, Tanderup K, Kirisits C, Pötter R

Kilde Radiother Oncol. 2021 Apr;157:24-31 Publiceringsdato 19 jan 2021

Abstrakt

Abstract

Objective: Multiple treatment options are used in early local-stage cervical cancer, including combinations of surgery with neoadjuvant/adjuvant radiotherapy and chemotherapy. Our aim was to determine the outcome for definitive chemoradiation with image guided brachytherapy (IGBT).

Methods: FIGO₁₉₉₄ staging system was used in our study. We included 123 patients with stage IB cervical cancer, treated at 12 centers with external beam radiotherapy (EBRT) ± Chemotherapy and IGBT. Three- and 5-year actuarial local control (LC), pelvic control (PC), overall survival (OS), cancer-specific survival (CSS) and late morbidity (CTCAE v 3.0) were computed.

Results: Median age was 48 (23-82) years. FIGO₁₉₉₄ stage distribution was: IB1 68% and IB2 32%; 41% of the entire cohort had nodal metastases and 73% squamous-cell carcinoma. MRI-based tumor size was >40 mm in 63%. Median EBRT dose was 45 (40-50) Gy; 84% received chemotherapy. At IGBT, mean CTV-HR D90 was 93 ± 17 Gy (EQD2₁₀). D2cc for bladder was 76 ± 14 Gy, rectum 66 ± 11 Gy, sigmoid 66 ± 10 Gy, bowel 67 ± 7 Gy (EQD2₃). At 43-months median follow-up, 9% of patients had systemic, 6% paraaortic, 3% pelvic-nodal and 2% local failure. Five-year LC was 98%, PC 96%, CSS 90%, OS 83%. Intestinal G3--4 morbidity was 8%, urinary 7% and vaginal 0%.

Conclusions: Chemoradiation with IGBT for FIGO₁₉₉₄ stage IB cervical cancer leads to excellent loco-regional control with limited morbidity. In IB node-negative disease, it can be regarded equivalent to surgery in terms of oncologic outcome. In tumors with unfavorable pre-treatment characteristics, chemoradiation is the first choice to avoid combining surgery with adjuvant therapy.